Gilead ends 2009 on a high thanks to Tamiflu and antivirals
This article was originally published in Scrip
Executive Summary
Gilead Sciences achieved its highest product sales to date during the fourth quarter of last year, posting an increase of almost 30% to $1.8 billion.